PMID-32605859 – GnRH Antagonist vs Agonist Prostate Cancer Meta-Analysis
Abufaraj M et al. "Differential Impact of Gonadotropin-releasing Hormone (GnRH) Agonists and Antagonists on Plasma Levels of Follicle-stimulating Hormone (FSH) in Patients with Advanced Prostate Cancer," European Urology, 2021;79(2):300-310. doi:10.1016/j.eururo.2020.06.002
Quick Reference
| Property | Value |
|---|---|
| PMID | 32605859 |
| DOI | 10.1016/j.eururo.2020.06.002 |
| Year | 2021 |
| Journal | European Urology |
| Study Type | Meta-Analysis |
| Evidence Level | I |
| Sample | 2,632 men across multiple RCTs |
| Peptide(s) Studied | GnRH antagonists (Degarelix) vs GnRH agonists (Leuprolide, Goserelin, Triptorelin) |
Key Findings
- Meta-analysis of RCTs comparing GnRH antagonists vs agonists in prostate cancer patients, totaling 2,632 men
- GnRH antagonists demonstrated significantly lower all-cause mortality compared to GnRH agonists
- Cardiovascular events were significantly reduced with GnRH antagonists vs agonists — a critical safety finding for the aging prostate cancer population
- GnRH antagonists achieve faster testosterone suppression without the initial testosterone flare seen with agonists
- FSH suppression was more complete with antagonists, which may explain the cardiovascular benefit given FSH receptor expression on vascular endothelium
- No significant differences in oncological efficacy (PSA response, testosterone suppression to castrate levels) between the two classes
Study Design
Systematic review and meta-analysis of randomized controlled trials directly comparing GnRH antagonists to GnRH agonists in men with advanced prostate cancer. Primary endpoints included overall survival, cardiovascular events, and hormonal suppression parameters.
Limitations
- Heterogeneity in cardiovascular event definitions across included trials
- Most data derived from the degarelix vs leuprolide comparison; limited data for other agents
- Follow-up periods varied across studies, potentially underestimating long-term differences
- Patient populations included a mix of metastatic and locally advanced disease
Clinical Relevance
This meta-analysis provides Level I evidence supporting GnRH antagonists over agonists for prostate cancer ADT, particularly in patients with pre-existing cardiovascular risk. The mortality and cardiovascular safety advantages of antagonists are clinically meaningful and should inform treatment selection. This is directly relevant to practitioners prescribing GnRH-modulating peptides and counseling patients on cardiovascular risk during hormonal therapy.
Related
#research #meta-analysis #evidence-level-I #cancer